Anticholinergic and sedative medicines: Prescribing considerations for people with dementia

Australian Family Physician

Volumn 41, Issue 1-2, 2012, Pages 45-49

  Bell, J Simon ^a   Mezrani, Carmel ^b   Blacker, Natalie ^a   LeBlanc, Tammy ^a   Frank, Oliver ^c   Alderman, Christopher P ^a   Rossi, Simone ^d   Rowett, Debra ^e   Shute, Russell ^d  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF NOTRE DAME   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d Australian Medicines Handbook   (Australia)

^e REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

Anticholinergic effects; Cholinergic antagonists; Cognition disorders; Dementia; Hypnotics and sedatives

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; DEMENTIA; HUMAN; METABOLISM;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; HISTAMINE ANTAGONISTS; HUMANS; HYPNOTICS AND SEDATIVES;

EID: 84858403597     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Access Economics. Keeping dementia front of mind: incidence and prevalence 2009-2050. 2009. Available at www.alzheimers.org.au/common/files/NAT/20090800_Nat__AE_FullKeepDemFrontMind.pdf [Accessed 31 May 2011].
2. N ishtala PS, Fois RA, McLachlan AJ, et al. Anticholinergic activity of commonly prescribed medications and neuropsychiatric adverse events in older people. J Clin Pharmacol 2009;49:1176-84.
3. Robinson M, Rowett D, Leverton A, et al. Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors. Pharmacoepidemiol Drug Saf 2009;18:659-64.
4. Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry 1987;44:418-26.
5. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002;50:836-42.
6. Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older people. Arch Intern Med 2008;168:508-13.
7. Carnahan RM, Lund BC, Perry PJ, et al. The Anticholinergic Drug Scale as a measure of drugrelated anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 2006;46:1481-6.
8. Rossi S, editor. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2011.
9. M inzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004;161:116-24.
10. Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther 2007;81:235-41.
11. Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2008;83:422-9.
12. Kumpula EK, Bell JS, Soini H, et al. Anticholinergic drug use and mortality among residents of long-term care facilities: a prospective cohort study. J Clin Pharmacol 2011;51:256-63.
13. Uusvaara J, Pitkala KH, Kautiainen H, et al. Association of anticholinergic drugs with hospitalization and mortality among older cardiovascular patients: A prospective study. Drugs Aging 2011;28:131-8.
14. Panula J, Puustinen J, Jaatinen P, et al. Effects of potent anticholinergics, sedatives and antipsychotics on postoperative mortality in elderly patients with hip fracture: a retrospective, population-based study. Drugs Aging 2009;26:963-71.
15. van Vliet P, van der Mast RC, van den Broek M, et al. Use of benzodiazepines, depressive symptoms and cognitive function in old age. Int J Geriatr Psychiatry 2009;24:500-8.
16. Hartikainen S, Lönnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci 2007;62:1172-81.
17. Pariente A, Dartigues JF, Benichou J, et al. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008;25:61-70.
18. Roth T. Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Med 2009;10:19-25.
19. Taipale HT, Bell JS, Gnjidic D, et al. Muscle strength and sedative load in community-dwelling people aged 75 years and older: a population-based study. J Gerontol A Biol Sci Med Sci 2011; Epub Sept 20 DOI 10.1093/gerona/glr170.
20. T aipale HT, Bell JS, Soini H, et al. Sedative load and mortality among residents of long-term care facilities: a prospective cohort study. Drugs Aging 2009;26:871-81.
21. Johnell K, Fastbom J. Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients. Drugs Aging 2008;25:871-7.
22. Tsakiris P, Oelke M, Michel MC. Drug-induced urinary incontinence. Drugs Aging 2008;25:541-9.
23. Starr JM. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease. J Am Geriatr Soc 2007;55:500-1.
24. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005;165:808-13.
25. Resnick NM. Urinary incontinence. Lancet 1995;346:94-9.
26. Arbus C, Gardette V, Bui E, et al. Antidepressant use in Alzheimer's disease patients: results of the REAL. FR cohort. Int Psychogeriatr 2010;22:120-8.
27. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 2011;59:577-85.
28. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
29. Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebocontrolled trial. Lancet 2011;378:403-11.
30. Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a metaanalysis. Can J Psychiatry 2007;52:248-55.
31. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011;2:CD008191.
32. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011;168:689-701.
33. Bombois S, Derambure P, Pasquier F, et al. Sleep disorders in aging and dementia. J Nutr Health Aging 2010;14:212-7.
34. David R, Zeitzer J, Friedman L, et al. Nonpharmacologic management of sleep disturbance in Alzheimer's disease. J Nutr Health Aging 2010;14:203-6.
35. Scherder E, Herr K, Pickering G, et al. Pain in dementia. Pain 2009;145:276-8.
36. Morrison RS, Siu AL. A comparison of pain and its treatment in advanced dementia and cognitively intact patients with hip fracture. J Pain Symptom Manage 2000;19:240-8.
37. Nygaard HA, Jarland M. Are nursing home patients with dementia diagnosis at increased risk for inadequate pain treatment? Int J Geriatr Psychiatry 2005;20:730-7.
38. Bell JS, Laitinen ML, Lavikainen P, et al. Use of strong opioids among community-dwelling persons with and without Alzheimer's disease in Finland. Pain 2011;152:543-7.
39. Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001;357:216-22.
40. Setoguchi S, Wang PS, Brookhart MA, et al. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008;56:1644-50.
41. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41.
42. Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry 2007;164:1491-8.
43. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebocontrolled trial. Lancet Neurol 2009;8:151-7.